Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm, Multi-center, Phase 2 Study of Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT07535762 is registered in ClinicalTrials.gov with Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT07535762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07535762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm, Multi-center, Phase 2 Study of Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
Lead sponsor
Shanghai Jiao Tong University School of Medicine
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 30, 2026
Completion date
December 30, 2028
Enrollment
36 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma (alcl) (alk-1 negative), nodal t-follicular helper cell lymphoma, peripheral t-cell lymphoma (ptcl nos)